Device Trial Radar · NCT06659536
Cefar URO - Symptomatic Treatment of Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- DJO UK LtdNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Donawa Lifescience Consulting S.r.l.
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling. The Cefar URO device features four pre-set programs (P1, P2, P3 and P4) and three custom programs. Although supporting data on the preset programs P1, P2, P3 are available for the clinically equivalent UROstim2 device, program P4 is unique to Cefar URO. Program P4 utilizes the parameters 20Hz and 200μs which are commonly reported in the literature for the stated indications but for which no data is available for the clinically equivalent UROstim2 device. The present study is therefore aimed to cover this data gap.
Conditions
- Overactive Bladder (OAB)
- Refractory Overactive Bladder
- Urinary Urgency and Frequency
Interventions
Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro DeviceDevice
Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: From enrollment to the end of Treatment at 16 weeks.
- Frequency of Overactive Bladder SymptomsTime frame: From enrollment to the end of Treatment at 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neuro-Urology Department, Tenon Hospital
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.